Compare MHO & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | XENE |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 1995 | 2014 |
| Metric | MHO | XENE |
|---|---|---|
| Price | $127.65 | $57.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $160.00 | $67.17 |
| AVG Volume (30 Days) | 172.4K | ★ 944.8K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.74 | N/A |
| Revenue | ★ $4,417,781,000.00 | $311,000.00 |
| Revenue This Year | $0.66 | N/A |
| Revenue Next Year | $6.97 | $2,436.26 |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $102.44 | $28.19 |
| 52 Week High | $158.92 | $62.91 |
| Indicator | MHO | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 54.82 |
| Support Level | $125.38 | $39.93 |
| Resistance Level | $127.81 | $59.44 |
| Average True Range (ATR) | 3.63 | 1.87 |
| MACD | 1.01 | -0.32 |
| Stochastic Oscillator | 91.47 | 32.47 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.